345 related articles for article (PubMed ID: 26734953)
1. Recommendations for presymptomatic genetic testing and management of individuals at risk for hereditary transthyretin amyloidosis.
Obici L; Kuks JB; Buades J; Adams D; Suhr OB; Coelho T; Kyriakides T;
Curr Opin Neurol; 2016 Feb; 29 Suppl 1(Suppl 1):S27-35. PubMed ID: 26734953
[TBL] [Abstract][Full Text] [Related]
2. Sixty years of transthyretin familial amyloid polyneuropathy (TTR-FAP) in Europe: where are we now? A European network approach to defining the epidemiology and management patterns for TTR-FAP.
Parman Y; Adams D; Obici L; Galán L; Guergueltcheva V; Suhr OB; Coelho T;
Curr Opin Neurol; 2016 Feb; 29 Suppl 1(Suppl 1):S3-S13. PubMed ID: 26734951
[TBL] [Abstract][Full Text] [Related]
3. Management of asymptomatic gene carriers of transthyretin familial amyloid polyneuropathy.
Schmidt HH; Barroso F; González-Duarte A; Conceição I; Obici L; Keohane D; Amass L
Muscle Nerve; 2016 Sep; 54(3):353-60. PubMed ID: 27273296
[TBL] [Abstract][Full Text] [Related]
4. First European consensus for diagnosis, management, and treatment of transthyretin familial amyloid polyneuropathy.
Adams D; Suhr OB; Hund E; Obici L; Tournev I; Campistol JM; Slama MS; Hazenberg BP; Coelho T;
Curr Opin Neurol; 2016 Feb; 29 Suppl 1(Suppl 1):S14-26. PubMed ID: 26734952
[TBL] [Abstract][Full Text] [Related]
5. Familial amyloid polyneuropathy.
Planté-Bordeneuve V; Said G
Lancet Neurol; 2011 Dec; 10(12):1086-97. PubMed ID: 22094129
[TBL] [Abstract][Full Text] [Related]
6. [Treatment of familial amyloid polyneuropathy].
Adams D; Samuel D; Slama M
Presse Med; 2012 Sep; 41(9 Pt 1):793-806. PubMed ID: 22341949
[TBL] [Abstract][Full Text] [Related]
7. [Transthyretin Familial Amyloid Polyneuropathy - Disease Profile of a Multisystem Disorder].
Niemietz C; Röcken C; Schilling M; Stypmann J; Uhlig CE; Schmidt HH
Dtsch Med Wochenschr; 2018 Mar; 143(6):427-430. PubMed ID: 29544239
[TBL] [Abstract][Full Text] [Related]
8. Familial amyloid polyneuropathy: When does it stop to be asymptomatic and need a treatment?
Adams D; Beaudonnet G; Adam C; Lacroix C; Théaudin M; Cauquil C; Labeyrie C
Rev Neurol (Paris); 2016 Oct; 172(10):645-652. PubMed ID: 27663057
[TBL] [Abstract][Full Text] [Related]
9. "Red-flag" symptom clusters in transthyretin familial amyloid polyneuropathy.
Conceição I; González-Duarte A; Obici L; Schmidt HH; Simoneau D; Ong ML; Amass L
J Peripher Nerv Syst; 2016 Mar; 21(1):5-9. PubMed ID: 26663427
[TBL] [Abstract][Full Text] [Related]
10. [Familial amyloid polyneuropathies: therapeutic issues].
Adams D; Cauquil C; Théaudin M
Bull Acad Natl Med; 2012 Oct; 196(7):1333-45; discussion 1345-7. PubMed ID: 23815018
[TBL] [Abstract][Full Text] [Related]
11. Transthyretin familial amyloid polyneuropathy (TTR-FAP): Parameters for early diagnosis.
Escolano-Lozano F; Barreiros AP; Birklein F; Geber C
Brain Behav; 2018 Jan; 8(1):e00889. PubMed ID: 29568686
[TBL] [Abstract][Full Text] [Related]
12. Diagnostic pitfalls in sporadic transthyretin familial amyloid polyneuropathy (TTR-FAP).
Planté-Bordeneuve V; Ferreira A; Lalu T; Zaros C; Lacroix C; Adams D; Said G
Neurology; 2007 Aug; 69(7):693-8. PubMed ID: 17698792
[TBL] [Abstract][Full Text] [Related]
13. The diagnostic accuracy of Sudoscan in transthyretin familial amyloid polyneuropathy.
Castro J; Miranda B; Castro I; de Carvalho M; Conceição I
Clin Neurophysiol; 2016 May; 127(5):2222-7. PubMed ID: 27072093
[TBL] [Abstract][Full Text] [Related]
14. Quantitative sudomotor test helps differentiate transthyretin familial amyloid polyneuropathy from chronic inflammatory demyelinating polyneuropathy.
Fortanier E; Delmont E; Verschueren A; Attarian S
Clin Neurophysiol; 2020 May; 131(5):1129-1133. PubMed ID: 32217467
[TBL] [Abstract][Full Text] [Related]
15. [Application to transthyretin analysis].
Ueda M; Ando Y
Rinsho Byori; 2006 Jun; 54(6):601-8. PubMed ID: 16872010
[TBL] [Abstract][Full Text] [Related]
16. Early diagnosis of ATTR amyloidosis through targeted follow-up of identified carriers of TTR gene mutations.
Conceição I; Damy T; Romero M; Galán L; Attarian S; Luigetti M; Sadeh M; Sarafov S; Tournev I; Ueda M
Amyloid; 2019 Mar; 26(1):3-9. PubMed ID: 30793974
[TBL] [Abstract][Full Text] [Related]
17. Peripheral Blood Cell Gene Expression Diagnostic for Identifying Symptomatic Transthyretin Amyloidosis Patients: Male and Female Specific Signatures.
Kurian SM; Novais M; Whisenant T; Gelbart T; Buxbaum JN; Kelly JW; Coelho T; Salomon DR
Theranostics; 2016; 6(11):1792-809. PubMed ID: 27570551
[TBL] [Abstract][Full Text] [Related]
18. [Ocular involvement in familial amyloid polyneuropathy].
Rousseau A; Kaswin G; Adams D; Cauquil C; Théaudin M; Mincheva Z; M'garrech M; Labetoulle M; Barreau E
J Fr Ophtalmol; 2013 Nov; 36(9):779-88. PubMed ID: 24144522
[TBL] [Abstract][Full Text] [Related]
19. Follow-up in transthyretin familial amyloid polyneuropathy: Useful investigations.
Escolano-Lozano F; Geber C; Barreiros AP; Birklein F
J Neurol Sci; 2020 Jun; 413():116776. PubMed ID: 32203746
[TBL] [Abstract][Full Text] [Related]
20. Recent advances in transthyretin amyloidosis therapy.
Ueda M; Ando Y
Transl Neurodegener; 2014; 3():19. PubMed ID: 25228988
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
